世界卫生组织《结核分枝杆菌耐药相关基因突变目录及其临床应用指南》解读  

Interpretation of Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance published by World Health Organization

作　　者：王玉峰 逄宇 WANG Yu-feng;PANG Yu(Department of Bacteriology and Immunology,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院细菌免疫室,北京101149

出　　处：《中国临床新医学》2022年第10期900-906,共7页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：国家自然科学基金项目(编号:82072243)。

摘　　要：耐药结核病是我国面临的重大公共卫生问题。分子诊断技术的不断发展促进了耐药结核病患者的早期诊断,但是不同耐药相关基因突变类型结果的解读成为分子耐药诊断领域的首要挑战。世界卫生组织于2021年出版了《结核分枝杆菌耐药相关基因突变目录及其临床应用指南》,旨在规范结核分枝杆菌分子耐药结果解读,特别是对于基于二代测序技术获得的结核分枝杆菌菌株获得的突变信息进行深入剖析,以期为临床提供更准确的耐药检测报告,也为耐药结核分子诊断技术在我国的推广使用奠定基础。Drug-resistant tuberculosis is a major public health problem in China.The continuous development of molecular diagnostic technology has promoted the early diagnosis of drug-resistant tuberculosis patients,but the interpretation of the results of different drug resistance-related gene mutation types has become the primary challenge in the field of molecular drug resistance diagnosis.In 2021,World Health Organization published Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance,aiming to standardize the interpretation of molecular drug resistance results of Mycobacterium tuberculosis,especially to conduct in-depth analysis of mutation information obtained by Mycobacterium tuberculosis strains based on the next generation sequencing technology,so as to provide more accurate drug resistance detection report for clinical use.It also lays a foundation for the popularization and use of molecular diagnostic technology for drug-resistant tuberculosis in China.

关 键 词：结核分枝杆菌 药物敏感性试验 耐药 高通量测序 

分 类 号：R378.911[医药卫生—病原生物学]